医学部 耳鼻咽喉科学講座

翁長 龍太郎

オナガ リュウタロウ  (Ryutaro Onaga)

基本情報

所属
学校法人 自治医科大学 耳鼻咽喉科
(兼任) 臨床腫瘍科 助教
国立研究開発法人国立がん研究センター 東病院 頭頸部内科 外来研究員

研究者番号
50812864
ORCID ID
 https://orcid.org/0000-0002-6422-4033
J-GLOBAL ID
202401017612716574
researchmap会員ID
R000066410

学歴

 1

論文

 18

MISC

 43
  • Nobukazu Tanaka Tomohiro, Enokida Susumu, Okano Takao, Fujisawa Ryutaro, Onaga Yuta, Hoshi Hideki Tanaka, Akihisa Wada, Masanobu Sato Naohiro, Takeshita Takeshi Fujisawa, Sadamoto Zenda, Makoto Tahara
    ESMO Asia Congress 2024_#2183 35 S1561-S1561 2024年12月  
  • Hirofumi Kuno, Takashi Hiyama, Tomoaki Sasaki, Shingo Sakashita, Ryutaro Onaga, Toshifumi Tomioka, Yoshihisa Muramatsu, Naruomi Akino, Hiroki Taguchi, Kotaro Sekiya, Tatsushi Kobayashi.
    RSNA2024 2024年12月  
  • 翁長 龍太郎, 榎田, 智弘, 檜山, 貴志, 田中, 伸和, 星, 裕太, 田中, 英基, 岸田, 拓磨, 藤澤, 孝夫, 岡野, 晋, 久野, 博文, 田原 信
    第48回頭頸部癌学会_第20群(画像) O-142 2024年6月  
  • Ryutaro Onaga, Tomohiro Enokida, Takashi Hiyama, Nobukazu Tanaka, Yuta Hoshi, Hideki Tanaka, Takao Fujisawa, Susumu Okano, Hirofumi Kuno, Makoto Tahara
    Journal of Clinical Oncology 42(16_suppl) 6034-6034 2024年6月1日  筆頭著者
    6034 Background: Extranodal extension (ENE) of nodal metastasis is a significant prognostic factor in p16-negative SCCHN and is classified as N3b by the AJCC 8th edition. Therefore, pretreatment determination of ENE has significant clinical implications in SCCHN, and iENE has just recently been proposed. We previously discussed association with pathological ENE and iENE (Jpn J Radiol. 2020;38(6):489-506.). However, the role of iENE in non-surgical sequential therapy remains unclear. Methods: We retrospectively reviewed patients with LASCCHN originating from the oropharynx, hypopharynx, and larynx who received enhanced computed tomography (CT), then treated with induction chemotherapy (IC) with paclitaxel, carboplatin, and cetuximab followed by chemoradiotherapy (CRT) from 2013 to 2022 in our hospital. Two radiologists specializing in head and neck cancer blindly annotated the status of iENE in baseline CT images by the previously reported criteria (Oral Oncol. 2022;125:105716.). Multivariate analysis variables for event-free survival (EFS) and overall survival (OS) included the presence or absence of iENE, a response to IC, clinical T-category, performance status, smoking status, etc. Results: In the 88 patients, 67 (76.1%) had iENE and 21 (23.9%) did not at baseline. In the former and latter group, stage II/III/IV were 10.4%/26.9%/62.7% and 0%/28.6%/71.4%, HPV-positive were 37.3% and 28.6%, respectively. With the median follow-up of 37.4 months (range: 6.7-108.8), the former had significantly shorter EFS (3-y EFS: 41.9% vs. 75.6%, hazard ratio [HR]; 2.9 (1.2-7.4), p-value; 0.02) and OS (3-y OS: 72.8% vs. 100%, HR; Inf (0.01-Inf), p-value=0.003). Multivariate analysis identified the presence of iENE (HR for EFS: 2.80, 95%CI: 0.97-8.05, HR for OS: 2.93, 95%CI: 1.01-8.44) and unresponsiveness to IC (HR for EFS: 2.47, 95%CI: 1.31-4.68, HR for OS: 2.87, 95%CI: 1.13-7.26) as mutually independent unfavorable prognostic factors for both EFS and OS. Furthermore, classification based on the two factors could identify the population with a worse prognosis (Table). Conclusions: In the sequential therapy of IC followed by CRT, the current study revealed for the first time that subjects with an iENE at baseline, together with an unsatisfactory response to IC would require special attention, such as more intensified post-treatment follow-up as well as additional therapeutic interventions to improve their prognosis. [Table: see text]
  • 翁長 龍太郎, 富岡 利文, 西谷 友樹雄, 岡野 渉, 篠﨑 剛, 松浦 一登, 林 隆一
    第33回日本頭頸部外科学会総会 2024年2月  

担当経験のある科目(授業)

 2